• FirefoxInstall the new Firefox »
  •  Dow Down 1.11% Nasdaq Down 0.94%

    Keryx Biopharmaceuticals Inc. (KERX)

    -NasdaqCM
    12.73 Down 0.31(2.38%) Mar 31, 4:00PM EDT
    |Pre-Market : 12.73 4:36PM EDT
    Add to Portfolio
    Prev Close:13.04
    Open:12.96
    Bid:11.45 x 1000
    Ask:N/A
    1y Target Est:24.25
    Beta:5.99
    Earnings Date:May 6 - May 11 (Est.)
    Day's Range:12.66 - 13.03
    52wk Range:10.85 - 18.48
    Volume:1,216,866
    Avg Vol (3m):1,762,140
    Market Cap:1.32B
    P/E (ttm):N/A
    EPS (ttm):-1.23
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Headlines

    » More Headlines for KERX

    Comparison

    Symbol% ChgMkt Cap
    KERXDown 2.38%1.32B
    BAXDown 0.38%37.17B
    SHPGDown 1.11%46.81B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):124.79
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-0.94
    Quarterly EPS Est (Mar-15) :-0.29
    Mean Recommendation*:1.8
    PEG Ratio (5 yr expected):-0.13

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback